Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Actinogen Medical Limited maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions currently in progress. These actions are spread across 2 distinct art units. Prosecution is being handled by 2 distinct examiners.
The busiest examiner identified is STOCKTON, LAURA LYNNE, who is responsible for 1 busiest examiner pending office action. This 1 action is part of the 2 pending office actions for the portfolio. The remaining action is handled by another of the 2 distinct examiners. This distribution requires the applicant to manage separate tracks of communication and technical negotiation.
With 2 distinct art units involved, the legal team must tailor its responses to the specific requirements of each unit. The presence of 2 distinct examiners means that the prosecution strategy must account for different perspectives. While STOCKTON, LAURA LYNNE handles 1 pending office action, the overall portfolio management must address the different examiner styles present across the active cases for Actinogen Medical Limited.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.6% |
| KUCHARCZK, JED A | 1 | 80.8% | +15.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17764922 | MEDICINAL COGNITIVE TREATMENTS | KUCHARCZK, JED A | 8d overdue |
| 18252025 | Process for Preparing Heterocyclic Methanone Compounds and AZA-Bicyclo Intermediates Thereof | STOCKTON, LAURA LYNNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17764922 | MEDICINAL COGNITIVE TREATMENTS | KUCHARCZK, JED A | 8d overdue |
| 18252025 | Process for Preparing Heterocyclic Methanone Compounds and AZA-Bicyclo Intermediates Thereof | STOCKTON, LAURA LYNNE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18252025 | Process for Preparing Heterocyclic Methanone Compounds and AZA-Bicyclo Intermediates Thereof | STOCKTON, LAURA LYNNE | 1626 | §102§103Other | Non-Final OA | — | Pending | Oct 09, 2023 |
| 17764922 | MEDICINAL COGNITIVE TREATMENTS | KUCHARCZK, JED A | 1623 | §102§103 | Final Rejection | 8d overdue | Pending | Mar 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialActinogen Medical Limited has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Laura Lynne Stockton has the most, with 1 of Actinogen Medical Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.